Loading clinical trials...

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension | Clinical Trials | Clareo Health

COMPLETED

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

NCT02858791•Northwell Health

Summary

The investigators will investigate the interrelationship of macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH.

Detailed Description

The investigators will test our hypothesis and accomplish our objectives by pursuing three Specific Aims: To investigate the interrelationship between macrophage migration inhibitory factor (MIF) and free T4 in patients with PAH with a working hypothesis that an increased release of MIF into the pulmonary vasculature during cardiopulmonary exercise changes the normal balance between plasma MIF and T4.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Subject must be at least 18 years of age and have confirmed pulmonary hypertension (PH) and interstitial lung disease (ILD).
•ILD was identified on high resolution computed tomography along with a total lung capacity (TLC) \<70% of predicted value on pulmonary function tests (PFTs) with no evidence of pulmonary hypertension on echocardiogram.
•PAH group patients were defined as patients with a mean pulmonary artery pressure \>25 mmHg at rest and a wedge pressure of \<15 mmHg (millimeters of mercury), measured by right heart catheterization (WHO group I PAH).
•PH+ILD group, subjects with evidence of ILD on high resolution CT Scan and mean pulmonary artery pressure \>25 mmHg on right heart catheterization.
•Patient with evidence of Chronic thromboembolic disease on CT angiogram and mean pulmonary artery pressure \>25mmHg on right heart catheterization. (WHO group IV)
•Patient with Pulmonary Hypertension due to other conditions, such as Sarcoidosis, Gauchers disease, Hemolytic Anemia and Myeloproliferative disorders.
•Normal control group: Subjects without cardiopulmonary disease, with a normal PFT and ECG.

Exclusion Criteria

•Failure to obtain informed consent;
•Pregnancy
•Subjects with cardiopulmonary disease other than PH and ILD;
•Unexplained abnormal PFT, ECG, Routine blood/chemistries test
•History or existing other sever organ/system diseases
•Defined Acute pulmonary embolism
•Age \< 18 years

Locations (1)

Northwell Health

New Hyde Park, New York, United States

Key Dates

Start Date

February 1, 2013

Primary Completion Date

December 21, 2017

Completion Date

December 21, 2017

Last Updated

January 9, 2018

Enrollment

ACTUAL participants

Conditions

Pulmonary HypertensionPulmonary Arterial HypertensionInterstitial Lung Disease

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITINGPHASE2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Preliminary Human Trials of F230 Tablets

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)